Tolerx, Inc. Employee Directory
Biotechnology ResearchMassachusetts, United States2-10 Employees
Tolerx, Inc. is a biotechnology research company based in Cambridge, Massachusetts. The firm focuses on immunology, developing first-in-class drug candidates aimed at normalizing immune responses to treat type 1 diabetes, other autoimmune diseases, and cancer. Its lead candidate, otelixizumab, targets T cells and is in Phase 3 development for type 1 diabetes, with GlaxoSmithKline as a partner, while TRX518 targets cancer and is in Phase 1. Additional candidates include TRX1, an anti-CD4 antibody evaluated for managing aberrant immune responses, and two preclinical programs, TRX585 and TRX385, exploring potential cancer and chronic viral infection therapies. The company operates as a privately held entity with a relatively small team and is positioned within the biotechnology research sector, pursuing immunotherapy approaches to modulate immune activity for therapeutic benefit.